Menopausal Hormone Therapy Reshapes Microbiome Responses Beyond Symptom Relief
Oral menopausal hormone therapy did more than ease climacteric symptoms in perimenopausal women. In a cohort of 356 women treated for 6 months with estradiol and dydrogesterone, the intervention improved neuroendocrine, metabolic and symptom outcomes while also producing measurable, site-specific changes in the microbiome.
The most striking shifts appeared where estrogen biology has the strongest local footprint. The vaginocervical and urinary niches underwent the most pronounced restructuring, while the gut changed far less. In practical terms, the hormonal intervention did not act as a uniform systemic pressure on every microbial ecosystem. It left a distinct microbial signature in reproductive and urinary sites, with only modest influence on the intestinal community.
Vaginocervical Communities Shifted Toward Lactobacillus Dominance
The intervention increased Lactobacillus crispatus in the vaginocervical microbiome and reduced Gardnerella vaginalis. Those two organisms sit on opposite sides of a familiar clinical divide: Lactobacillus-rich communities tend to support a lower-pH, more protective vaginal environment, while Gardnerella-associated patterns often track with dysbiosis.
A single sentence captures the biological direction of travel: estrogen replacement pushed the vaginocervical ecosystem toward a healthier state.
The urinary niche also changed, although the abstract does not provide the same level of species-level detail for that compartment. Even without those specifics, the pattern matters because it points to a local estrogen effect that reaches beyond symptom control. Estrogen influences epithelial maturation, glycogen availability and the substrates that favor Lactobacillus growth, making the microbial response biologically plausible rather than incidental.
Baseline Microbiome Status Helped Predict Treatment Benefit
The study moved beyond describing microbiome change and asked a more clinically useful question: which women responded best? Baseline vaginocervical L. crispatus abundance predicted greater post-treatment colonization in both the vaginocervical and urinary niches, along with a superior improvement in Female Sexual Function Index scores.
This suggests that the starting microbial environment shapes how fully the mucosal ecosystem can respond to hormone therapy. Women who already carried more of the protective organism at baseline were more likely to amplify that advantage after treatment. The finding also links microbial state to a patient-centered outcome, sexual function, rather than to a laboratory endpoint alone.
The vaginocervical community structure itself carried prognostic information. Women whose baseline communities were dominated by G. vaginalis shifted most strongly toward healthier communities after treatment. By contrast, women with more diversified baseline communities improved least. In other words, not all dysbiosis behaved the same way. A community already dominated by a clearly unfavorable taxon seemed more reprogrammable than a broader mixed community, which may represent a more entrenched or less hormone-responsive state.
Gut Community Type Also Separated Hormonal Responders From Nonresponders
The gut microbiome added another layer of heterogeneity. Baseline gut community type influenced how strongly women benefited from therapy, with Phocaeicola vulgatus-dominated individuals showing greater hormonal responsiveness, better clinical outcomes and a higher likelihood of achieving 4-week rapid clinical remission than those dominated by Prevotella copri.
That is an unusually direct line between microbial ecology and short-term clinical response. The distinction was not merely academic taxonomy. It separated women who appeared to respond briskly from those who improved less, implying that the gut microbiome may function as a predictor of hormonal sensitivity rather than as a passive bystander.
The mechanism is not spelled out in the article, but the clinical logic is straightforward. Gut microbes can influence estrogen metabolism, immune signaling and systemic inflammatory tone, any of which could alter the response to menopausal hormone therapy. A different microbial starting point may therefore produce a different endocrine and symptom trajectory even when the medication is identical.
Precision MHT Starts With Microbial Typing, Not One-Size-Fits-All Assumptions
The study supports a precision framework for menopausal hormone therapy in perimenopausal women. Instead of assuming that all patients with climacteric symptoms will respond in the same way, the data point toward stratification by baseline vaginocervical and gut microbial communities.
That approach could eventually help clinicians identify who is likely to gain the most from hormone treatment, who may need closer follow-up and who might require a different strategy altogether. It also reframes the microbiome as part of the endocrine treatment response, not just a secondary feature of reproductive aging.
The strongest signal came from the local genital tract, where estradiol-containing therapy aligned the microbiome toward Lactobacillus dominance and away from Gardnerella. The gut signal was smaller overall, yet it still carried predictive value for response. Those two observations together suggest a layered model: local hormone effects reshape the reproductive tract directly, while baseline intestinal ecology helps determine the broader physiologic response.
Clinical Questions Left Open by the Trial Design
Several important details remain unaddressed in the abstract. The analysis does not provide the full magnitude of the microbiome shifts, the proportion of women achieving each outcome, or the durability of the microbial changes beyond the 6-month treatment window. It also does not establish whether the microbiome changes were a cause of symptom improvement, a consequence of improved hormonal status, or both.
The study does, however, make one point with unusual clarity: perimenopausal women are not biologically interchangeable when it comes to hormone therapy. Baseline microbial state separated better responders from poorer responders, and the reproductive tract microbiome changed in a direction that fits established mucosal physiology. Future work will need to determine whether microbiome profiling can be converted into a practical clinical tool for selecting and monitoring patients before menopausal hormone therapy is started.